Clinic
Christus Santa Rosa Health Care Corporation
Christus Santa Rosa Health Care Corporation was paid $10.73M by Medicaid between Apr 2019 and Dec 2024, across 128 billing codes. Its largest line is 99284, emergency room visit (serious) — 52% of everything it billed.
33Billing provider infoCHRISTUS SANTA ROSA HEALTH CARE CORPORATION
SAN ANTONIO, TX 78251
SAN ANTONIO, TX 78251
33aNPI1194787218assigned 04/04/2006
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$10.73M
24GClaims200,742
24DCodes billed128
24AFirst – last monthApr 2019 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#42 of 320
Median peer was paid$205K
This provider vs. median52×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 313 | $4K | |
| 2020 | 4,486 | $274K | |
| 2021 | 42,668 | $1.78M | |
| 2022 | 70,482 | $3.80M | |
| 2023 | 56,387 | $3.67M | |
| 2024incomplete | 26,406 | $1.21M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 52% | 13,366 | 12,528 | $5.58M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 29,288 | 28,359 | $2.16M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.9% | 1,842 | 1,681 | $955K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.2% | 5,575 | 4,870 | $238K |
| 87428 | 1.6% | 3,119 | 3,050 | $169K | |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.6% | 2,791 | 2,739 | $166K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 17,975 | 16,214 | $119K |
| 80053 | Comprehensive metabolic panel | 1.1% | 14,984 | 13,626 | $116K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,229 | 2,185 | $99K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,249 | 2,203 | $79K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,073 | 1,046 | $73K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | <1% | 833 | 828 | $73K |
116 more codes
| G0378 | Hospital observation service, per hour | <1% | 54 | $68K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,045 | $68K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 500 | $68K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 580 | $53K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,528 | $48K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,090 | $47K |
| D0120 | Dental checkup, returning patient | <1% | 1,519 | $43K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,225 | $42K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 916 | $31K |
| D1120 | Dental cleaning, child | <1% | 830 | $30K |
| 81001 | <1% | 8,984 | $26K | |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 1,602 | $23K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 43 | $22K |
| 76801 | <1% | 247 | $20K | |
| 84484 | <1% | 3,503 | $20K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,661 | $18K |
| 87081 | <1% | 1,902 | $18K | |
| D1110 | Prophylaxis - adult | <1% | 267 | $14K |
| 83690 | <1% | 3,009 | $14K | |
| 84702 | <1% | 1,011 | $12K | |
| 83880 | <1% | 1,109 | $12K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 175 | $12K |
| 84703 | <1% | 1,641 | $10K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,546 | $10K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 215 | $10K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 157 | $9K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 280 | $8K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 175 | $8K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,132 | $8K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 161 | $6K |
| 43235 | <1% | 13 | $6K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 343 | $6K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 246 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,165 | $5K |
| 82803 | <1% | 563 | $5K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 159 | $5K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,158 | $5K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,187 | $5K |
| 94760 | <1% | 221 | $4K | |
| 83605 | <1% | 887 | $4K | |
| 87420 | <1% | 163 | $3K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 44 | $3K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,136 | $3K |
| D0220 | Intraoral - periapical first radiographic image | <1% | 292 | $3K |
| D0272 | Bitewings - two radiographic images | <1% | 143 | $3K |
| 85610 | <1% | 2,035 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 780 | $3K |
| 85730 | <1% | 1,578 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,069 | $3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 202 | $2K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 56 | $2K |
| 83735 | <1% | 1,123 | $2K | |
| 82375 | <1% | 510 | $2K | |
| 73564 | <1% | 34 | $2K | |
| 82330 | <1% | 563 | $2K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 36 | $2K |
| 0240U | <1% | 570 | $2K | |
| 81025 | <1% | 288 | $2K | |
| D0145 | Oral evaluation for a patient under three years of age | <1% | 15 | $2K |
| 83050 | <1% | 494 | $2K | |
| 93976 | <1% | 17 | $1K | |
| 85027 | <1% | 958 | $1K | |
| D1351 | Sealant - per tooth | <1% | 48 | $1K |
| 86850 | <1% | 93 | $1K | |
| D0274 | Bitewings - four radiographic images | <1% | 44 | $1K |
| 87040 | <1% | 268 | $1K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 21,297 | $991.20 |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 95 | $955.33 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 235 | $937.50 |
| 72100 | <1% | 12 | $903.50 | |
| 86900 | <1% | 569 | $878.37 | |
| 86901 | <1% | 569 | $850.42 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 567 | $800.75 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 547 | $767.64 |
| 80320 | <1% | 70 | $761.11 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 425 | $734.77 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 450 | $696.55 |
| 81003 | <1% | 706 | $653.29 | |
| 87186 | <1% | 195 | $581.32 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 287 | $553.22 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 172 | $484.81 |
| 82077 | <1% | 45 | $462.48 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 251 | $448.53 |
| 84132 | <1% | 309 | $425.85 | |
| 82435 | <1% | 283 | $395.30 | |
| 80076 | <1% | 58 | $392.44 | |
| 84295 | <1% | 251 | $379.87 | |
| 82947 | <1% | 284 | $348.15 | |
| 87077 | <1% | 111 | $303.43 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 81 | $241.00 |
| D0140 | Limited oral evaluation - problem focused | <1% | 12 | $225.36 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 91 | $177.39 |
| 73030 | <1% | 12 | $153.50 | |
| 80179 | <1% | 13 | $133.42 | |
| 80143 | <1% | 13 | $133.42 | |
| 80061 | Lipid panel | <1% | 27 | $105.75 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 200 | $101.24 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 79 | $92.89 |
| 82962 | <1% | 2,390 | $82.67 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 13 | $62.60 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 17 | $57.25 |
| 96376 | <1% | 71 | $21.17 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 25 | $17.92 |
| 84100 | <1% | 14 | $14.96 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 14 | $13.27 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 427 | $13.00 |
| A9270 | Non-covered item or service | <1% | 2,646 | $7.82 |
| J2704 | Injection, propofol, 10 mg | <1% | 153 | $2.02 |
| D0603 | 0% | 1,203 | $0.00 | |
| D0602 | 0% | 275 | $0.00 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 12 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 14 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 152 | $0.00 |
| A6021 | Collagen dressing, sterile, size 16 sq. in. or less, each | 0% | 27 | $0.00 |
| 77080 | 0% | 28 | $0.00 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCHEN, STEVEN (CFO)
| Provider | Location | Paid |
|---|---|---|
| Bryn Mawr Foot & Ankle Center, LLC | Bryn Mawr, PA | $39K |
| Premier Family Health Care, a Professional Corporation | Bakersfield, CA | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.